The effect of postoperative and primary radiation therapy on delivered dose of adjuvant Cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF) chemotherapy in breast cancer

Jedd F. Levine, C. Norman Coleman, Richard S. Cox, Gordon R. Ray, William M. Rogoway, Alvaro Martinez, Frank E. Stockdale

Research output: Contribution to journalArticlepeer-review

Abstract

The dose of adjuvant chemotherapy for breast cancer may be an important factor in the success of the treatment program. In a retrospective analysis, the authors determined whether patients who were irradiated either postoperatively (N = 29) or as part of primary treatment (N = 13) received a lower dose of adjuvant Cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF) chemotherapy than patients who were not irradiated (N = 42). The 84 evaluable patients received either cyclical or weekly CMF. Radiation therapy included the chest wall or breast and regional lymph nodes. The mean percentage of maximum chemotherapy dose delivered (59.9% versus 73.5%; P < 0.001), mean percent prescribable or theoretical maximum dose (83.1% versus 91.3%; P < 0.001), and mean leukocyte count (3.9 versus 4.5; P < 0.01) during therapy were statistically significantly lower in irradiated patients. The lower delivered chemotherapy dose in irradiated patients was not related to the radiation dose to the thoracic spine. The authors conclude that radiation therapy to the chest wall or breast and regional lymph nodes reduces the dose of adjuvant CMF that can be delivered.

Original languageEnglish (US)
Pages (from-to)237-241
Number of pages5
JournalCancer
Volume53
Issue number2
DOIs
StatePublished - Jan 15 1984

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The effect of postoperative and primary radiation therapy on delivered dose of adjuvant Cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF) chemotherapy in breast cancer'. Together they form a unique fingerprint.

Cite this